Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q3 2020 · 10-Q
Revenue$0.00$0.00−100.0% vs Q3 2019 Net Income$82.60M$82.60M−63.5% vs Q3 2019 EPS Diluted$0.71$0.71−63.6% vs Q3 2019 Operating Income$86,675,000−61.4% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$40,411,000N/M ended Sep 30, 2020 · filed Oct 30, 2020 · 30 d after period end